Meyka Pro banner
Mainz Biomed B.V.

Mainz Biomed B.V. Fundamental Analysis (NASDAQ: MYNZ)

MYNZ●NASDAQ
HealthcareMedical - Diagnostics & Research
$3.59
$0.03(0.84%)
U.S. Market opens in NaNh NaNm

Mainz Biomed B.V. Fundamental Analysis (NASDAQ: MYNZ)

Mainz Biomed B.V. (NASDAQ: MYNZ) shows weak financial fundamentals with a PE ratio of -5.10, profit margin of -16.96%, and ROE of -89.81%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.04
Current Ratio3.73

Areas of Concern

ROE-89.81%
Operating Margin-15.26%
Cash Position2.18%
We analyze MYNZ's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1665.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1665.2/100

We analyze MYNZ's fundamental strength across five key dimensions:

Efficiency Score

Weak

MYNZ struggles to generate sufficient returns from assets.

ROA > 10%
-87.38%

Valuation Score

Excellent

MYNZ trades at attractive valuation levels.

PE < 25
-5.10
PEG Ratio < 2
-0.04

Growth Score

Weak

MYNZ faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

MYNZ maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
3.73

Profitability Score

Weak

MYNZ struggles to sustain strong margins.

ROE > 15%
-8981.45%
Net Margin ≥ 15%
-16.96%
Positive Free Cash Flow
No

Key Financial Metrics

Is MYNZ Expensive or Cheap?

P/E Ratio

MYNZ trades at -5.10 times earnings. This suggests potential undervaluation.

-5.10

PEG Ratio

When adjusting for growth, MYNZ's PEG of -0.04 indicates potential undervaluation.

-0.04

Price to Book

The market values Mainz Biomed B.V. at 14.15 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

14.15

EV/EBITDA

Enterprise value stands at -3.99 times EBITDA. This is generally considered low.

-3.99

How Well Does MYNZ Make Money?

Net Profit Margin

For every $100 in sales, Mainz Biomed B.V. keeps $-16.96 as profit after all expenses.

-16.96%

Operating Margin

Core operations generate -15.26 in profit for every $100 in revenue, before interest and taxes.

-15.26%

ROE

Management delivers $-89.81 in profit for every $100 of shareholder equity.

-89.81%

ROA

Mainz Biomed B.V. generates $-87.38 in profit for every $100 in assets, demonstrating efficient asset deployment.

-87.38%

Following the Money - Real Cash Generation

Operating Cash Flow

Mainz Biomed B.V. generates limited operating cash flow of $-336.08K, signaling weaker underlying cash strength.

$-336.08K

Free Cash Flow

Mainz Biomed B.V. generates weak or negative free cash flow of $-344.91K, restricting financial flexibility.

$-344.91K

FCF Per Share

Each share generates $-0.08 in free cash annually.

$-0.08

FCF Yield

MYNZ converts -36.53% of its market value into free cash.

-36.53%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.10

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.04

vs 25 benchmark

P/B Ratio

Price to book value ratio

14.15

vs 25 benchmark

P/S Ratio

Price to sales ratio

15.20

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.73

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.90

vs 25 benchmark

ROA

Return on assets percentage

-0.87

vs 25 benchmark

ROCE

Return on capital employed

-0.90

vs 25 benchmark

How MYNZ Stacks Against Its Sector Peers

MetricMYNZ ValueSector AveragePerformance
P/E Ratio-5.1030.85 Better (Cheaper)
ROE-89.81%473.00% Weak
Net Margin-1696.04%5192.00% Weak
Debt/Equity0.020.12 Strong (Low Leverage)
Current Ratio3.735.76 Strong Liquidity
ROA-87.38%-1414.00% (disorted) Weak

MYNZ outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Mainz Biomed B.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ